Skip to content

Total debt at other companies

Replimune Group logo
Replimune GroupREPL
$79.21M+0.5%
CG Oncology logo
CG OncologyCGON
$7.58M+631%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$1.04M-2.0%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$31.0K0.0%
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation

See full
Market cap$693.87M+192%
Enterprise value$501.88M+220%
P/S5,595.7×-18,674×

Profitability

See full
Operating margin-28,000.8%+15,050pp
Net margin-15,156.5%-5,064pp
FCF margin-26,383.9%+14,851pp

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity-0.1×
Current ratio28×+23.4×

Where this comes from

Calculated from Candel Therapeutics, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s total debt?
Candel Therapeutics, Inc. (CADL) reported total debt of $2.84M in Q1 2026.
How has Candel Therapeutics, Inc.'s total debt changed year-over-year?
Candel Therapeutics, Inc.'s total debt decreased by 73.9% year-over-year, from $10.91M to $2.84M.
What is the long-term trend for Candel Therapeutics, Inc.'s total debt?
Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s total debt has grown at a 43.2% compound annual growth rate (CAGR), from $483K to $2.91M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.